1,120 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Darden Wealth Group Inc

Darden Wealth Group Inc acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,120 shares of the company’s stock, valued at approximately $219,000.

A number of other institutional investors also recently bought and sold shares of the business. Axxcess Wealth Management LLC grew its stake in shares of Zoetis by 17.4% in the 1st quarter. Axxcess Wealth Management LLC now owns 9,826 shares of the company’s stock valued at $1,663,000 after purchasing an additional 1,458 shares during the last quarter. Advisors Asset Management Inc. grew its position in Zoetis by 4.4% in the 1st quarter. Advisors Asset Management Inc. now owns 16,168 shares of the company’s stock valued at $2,736,000 after buying an additional 678 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in Zoetis by 178.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 639,352 shares of the company’s stock valued at $108,185,000 after buying an additional 409,522 shares during the period. 1832 Asset Management L.P. raised its position in Zoetis by 5.3% during the 1st quarter. 1832 Asset Management L.P. now owns 61,472 shares of the company’s stock worth $10,402,000 after buying an additional 3,099 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in shares of Zoetis in the 1st quarter worth $137,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.6 %

Shares of Zoetis stock opened at $176.71 on Friday. The business has a 50 day moving average price of $185.90 and a 200 day moving average price of $180.45. The company has a market capitalization of $79.73 billion, a P/E ratio of 33.22, a P/E/G ratio of 2.69 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.36 earnings per share. Sell-side analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ZTS shares. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.